Spots Global Cancer Trial Database for opdivo®
Every month we try and update this database with for opdivo® cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And Portugal | NCT05168436 | Renal Cell Carc... | 18 Years - | Bristol-Myers Squibb | ||
| A Study of Preferences of Participants and Oncologists for the Characteristics of the Treatment for Renal Cell Carcinoma (RCC) In Spain And Portugal | NCT05168436 | Renal Cell Carc... | 18 Years - | Bristol-Myers Squibb | ||
| A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma | NCT06022861 | Esophageal Squa... | LY01015 Fluorouracil Cisplatin Opdivo® | 18 Years - 75 Years | Shandong Boan Biotechnology Co., Ltd | |
| A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma | NCT06022861 | Esophageal Squa... | LY01015 Fluorouracil Cisplatin Opdivo® | 18 Years - 75 Years | Shandong Boan Biotechnology Co., Ltd | |
| A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | NCT02335918 | Squamous Cell C... Ovarian Carcino... Colorectal Canc... Renal Cell Carc... Glioblastoma (G... | Combination of ... | 18 Years - | Celldex Therapeutics | |
| A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | NCT05298592 | Advanced Cancer | BMS-986406 Nivolumab Carboplatin Pemetrexed Paclitaxel | 18 Years - | Bristol-Myers Squibb | |
| A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer | NCT05165264 | Gastric Cancer | 18 Years - | Bristol-Myers Squibb | ||
| A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | NCT05298592 | Advanced Cancer | BMS-986406 Nivolumab Carboplatin Pemetrexed Paclitaxel | 18 Years - | Bristol-Myers Squibb | |
| Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence | NCT04410445 | Melanoma Melanoma Stage ... Melanoma Stage ... Melanoma (Skin) | Bempegaldesleuk... Nivolumab | 12 Years - | Nektar Therapeutics | |
| A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) | NCT03729245 | Renal Cell Carc... Metastatic Rena... | bempegaldesleuk... sunitinib nivolumab cabozantinib | 18 Years - | Nektar Therapeutics | |
| A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO) | NCT05068609 | Squamous Cell C... | Nivolumab | 18 Years - | Bristol-Myers Squibb | |
| A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer | NCT03785925 | Urinary Bladder... Neoplasm Metast... | Bempegaldesleuk... Nivolumab | 18 Years - | Nektar Therapeutics | |
| A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer | NCT05165264 | Gastric Cancer | 18 Years - | Bristol-Myers Squibb |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
